| Package | dk.kip.rkkp.fhir.ig.core |
| Resource Type | ValueSet |
| Id | Immunoterapi |
| FHIR Version | R4 |
| Source | https://kip.rkkp.dk/fhir/https://build.fhir.org/ig/KIP-infrastructure/implementation-guide/ValueSet-Immunoterapi.html |
| URL | https://kip.rkkp.dk/fhir/ValueSet/Immunoterapi |
| Version | 2.12.0 |
| Status | active |
| Date | 2022-07-18T00:00:00+02:00 |
| Name | Immunoterapi |
| Title | Immunoterapi |
| Description | Immunoterapi |
No resources found
| CodeSystem | |
| ATC | WHO ATC |
| GenericValues | Generic values |
| TreatmentUnspecified | Treatment unspecified |
Note: links and images are rebased to the (stated) source
Generated Narrative: ValueSet Immunoterapi
This value set includes codes based on the following rules:
FHIRhttps://kip.rkkp.dk/fhir/CodeSystem/GenericValues| Code | Display | Definition |
| none | Ingen immunoterapi | None - used to choose none of the available values |
https://kip.rkkp.dk/fhir/CodeSystem/ATC| Code | Display | Definition |
| L01FA01 | Rituximab | L01FA01 - rituximab |
| L01FA03 | Obinutuzumab | L01FA03 - obinutuzumab |
| L01FA02 | Ofatumumab | L01FA02 - ofatumumab |
| L04AA | MabCampath | L04AA - Selective immunosuppressants |
| L01FX05 | Brentuximab vedotin (Adcetris) | L01FX05 - brentuximab vedotin |
| L01FX14 | Polatuzumab incl evt. Rituximab | L01FX14 - polatuzumab vedotin |
| L01FF | PD(L)1 hæmmere | L01FF - PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors |
https://kip.rkkp.dk/fhir/CodeSystem/TreatmentUnspecified| Code | Display | Definition |
| glofitamab | Glofitamabel Epcoritamab Incl evt. Rituximab | Glofitamab |
{
"resourceType": "ValueSet",
"id": "Immunoterapi",
"text": {
"status": "extensions",
"div": "<!-- snip (see above) -->"
},
"url": "https://kip.rkkp.dk/fhir/ValueSet/Immunoterapi",
"version": "2.12.0",
"name": "Immunoterapi",
"title": "Immunoterapi",
"status": "active",
"experimental": true,
"date": "2022-07-18T00:00:00+02:00",
"publisher": "Sundhedsvæsenets Kvalitetsinstitut with Trifork Digital Health A/S",
"contact": [
{
"name": "Sundhedsvæsenets Kvalitetsinstitut with Trifork Digital Health A/S",
"telecom": [
{
"system": "url",
"value": "https://trifork.com"
},
{
"system": "email",
"value": "rbk@trifork.com"
}
]
}
],
"description": "Immunoterapi",
"compose": {
"include": [
{
"system": "https://kip.rkkp.dk/fhir/CodeSystem/GenericValues",
"concept": [
{
"code": "none",
"display": "Ingen immunoterapi"
}
]
},
{
"system": "https://kip.rkkp.dk/fhir/CodeSystem/ATC",
"concept": [
{
"code": "L01FA01",
"display": "Rituximab"
},
{
"code": "L01FA03",
"display": "Obinutuzumab"
},
{
"code": "L01FA02",
"display": "Ofatumumab"
},
{
"code": "L04AA",
"display": "MabCampath"
},
{
"code": "L01FX05",
"display": "Brentuximab vedotin (Adcetris)"
},
{
"code": "L01FX14",
"display": "Polatuzumab incl evt. Rituximab"
},
{
"code": "L01FF",
"display": "PD(L)1 hæmmere"
}
]
},
{
"system": "https://kip.rkkp.dk/fhir/CodeSystem/TreatmentUnspecified",
"concept": [
{
"code": "glofitamab",
"display": "Glofitamabel Epcoritamab Incl evt. Rituximab"
}
]
}
]
}
}